NCT04214808Phase 1Completed

To Evaluate the Pharmacokinetics and Safety of AD-208

A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of AD-208

In the register

The register attaches this trial to AD-208 (low-dose dutasteride) (Addpharma), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.

What the registry records

Status: Completed
Declared phase: Phase 1
Sponsor: Addpharma Inc.
Participants (registry): 24
Start: January 2020
Primary completion: February 2020
Study completion: May 2020
Last registry update: December 2020
Countries: South Korea

Conditions studied: Androgenetic Alopecia

Interventions: AD-208, Avodart Soft Capsule 0.5mg

Full record on ClinicalTrials.gov ↗

Other trials of AD-208 (low-dose dutasteride)

NCT04825561Phase 3Completed
A Study to Evaluate the Efficacy and Safety of AD-208

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.